Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3829125 | 0.93 | ALDH1A1 (0.83) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL27347353 | 0.83 | ALDH1A1 (0.74) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL29623278 | 0.82 | ALDH1A1 (1.00) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL354679 | 0.82 | ALDH1A1 (1.00) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL5358823 | 0.82 | ALDH1A1 (0.71) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL7722058 | 0.81 | ALDH1A1 (0.48) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7808078 | 0.80 | ALDH1A1 (0.96) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL29540343 | 0.80 | ALDH1A1 (0.69) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| Water SCHEMBL29724498 | 0.80 | ALDH1A1 (0.96) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL851358 | 0.80 | ALDH1A1 (0.69) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 468 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2264786-A | — | — | None | — | — | JP | disclosed |
| EP-4713018-A1 | TRANSFECTION COMPOSITIONS SUITABLE FOR PRODUCING A BIOLOGICAL PRODUCT | PolyPlus Transfection (FR) | 2026-03-25 | — | — | EP | disclosed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250170117-A1 | MODULATORS OF ACKR3 AND USES THEREOF | INTERAX BIOTECH AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4486739-A1 | MODULATORS OF ACKR3 AND USES THEREOF | InterAx Biotech AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024236194-A1 | TRANSFECTION COMPOSITIONS SUITABLE FOR PRODUCING A BIOLOGICAL PRODUCT | POLYPLUS TRANSFECTION (FR) | 2024-11-21 | — | — | WO | disclosed |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-09-19 | — | — | US | disclosed |
| CN-112204009-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023166190-A1 | MODULATORS OF ACKR3 AND USES THEREOF | INTERAX BIOTECH AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| EP-4238970-A1 | MODULATORS OF ACKR3 AND USES THEREOF | InterAx Biotech AG (CH) | 2023-09-06 | — | — | EP | disclosed |
| EP-0013107-A1 | 16-Hydroxy-16-vinyl (or cyclopropyl)-prostan-1-ols and pharmaceutical compositions containing the same | AMERICAN CYANAMID COMPANY (US) | 1980-07-09 | — | — | EP | disclosed |
| US-4206151-A | BRONCHODILATOR, ANTISECRETORY, HYPOTENSIVE | AMERICAN CYANAMID COMPANY (US) | 1980-06-03 | — | — | US | disclosed |
| US-4192677-A | ELECTROGRAPHIC CHARGE TRANSFER COMPOUNDS | RICOH CO., LTD. (JP) | 1980-03-11 | — | — | US | disclosed |
| EP-0002590-A1 | Novel prostaglandin compounds, processes for the preparation thereof and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-06-27 | — | — | EP | disclosed |
| EP-0001989-A1 | Substituted mercapto acid amides, process for their preparation, pharmaceutical composition containing same and their use | MERCK & CO. INC. (US) | 1979-05-30 | — | — | EP | disclosed |
| US-4141729-A | 1,3,4-Oxadiazole derivatives and electrophotographic plates containing same | RICOH COMPANY, LTD. (JP) | 1979-02-27 | — | — | US | disclosed |
| US-4139533-A | ANTIARRHYTHMIA AGENTS | BRISTOL-MYERS COMPANY (US) | 1979-02-13 | — | — | US | disclosed |
| US-4123440-A | ANTIARRHYTHMIA AND ANTIFIBRILLATORY AGENTS | BRISTOL-MYERS COMPANY (US) | 1978-10-31 | — | — | US | disclosed |
| US-4122273-A | PROPHYLACTIC, ANTIARRHYTHMIC | BRISTOL-MYERS COMPANY (US) | 1978-10-24 | — | — | US | disclosed |
| US-4088652-A | Acylazabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170117-A1 | MODULATORS OF ACKR3 AND USES THEREOF | ACKR3, PROKR2, PROKR1 | ALDH1A1 3187/4885HPGD 1401/4885ALOX15 3504/4885 |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ALDH1A1 3433/4885HPGD 849/4885ALOX15 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.